Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BIIB033 in Healthy Japanese Subjects
NCT02641041Phase 1Completed
- Sponsor
- Biogen
- Start
- Feb 2016
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of opicinumab in multiple sclerosis (MS) and Central nervous system demyelinating disease (3 cohorts), sponsored by Biogen. Primary endpoints: Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of participants with clinically significant laboratory parameters and 4 more. Started Feb 2016; status: completed.
02
Drugs
opicinumab
03
Conditions
multiple sclerosis (MS)Central nervous system demyelinating disease
Beyond the preview
Go deeper on NCT02641041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641041.